Liminal BioSciences Inc. filed its 20-F on Mar 15, 2023 for the period ending Dec 31, 2022. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Liminal BioSciences Inc.
Equities
PJ2
CA53272L2021
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+22.56% | 46.71B | |
+48.83% | 41.8B | |
-1.51% | 41.52B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
-0.14% | 12.14B | |
-0.47% | 12.08B | |
+26.45% | 11.98B |